Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Drops By 24.6%

GlucoTrack, Inc. (NASDAQ:GCTK) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 28,292 shares, a drop of 24.6% from the February 12th total of 37,508 shares. Approximately 2.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 37,296 shares, the short-interest ratio is currently 0.8 days. Based on an average daily trading volume, of 37,296 shares, the short-interest ratio is currently 0.8 days. Approximately 2.9% of the shares of the stock are short sold.

GlucoTrack Price Performance

GlucoTrack stock traded down $0.06 during mid-day trading on Friday, hitting $1.21. 77,806 shares of the company traded hands, compared to its average volume of 40,606. GlucoTrack has a one year low of $1.11 and a one year high of $30.51. The stock has a market cap of $1.22 million, a price-to-earnings ratio of -0.03 and a beta of 0.33. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.53 and a current ratio of 1.53. The stock has a fifty day moving average price of $2.38 and a 200-day moving average price of $4.64.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, GlucoTrack currently has a consensus rating of “Sell”.

Institutional Trading of GlucoTrack

A number of hedge funds have recently made changes to their positions in GCTK. Bank of America Corp DE grew its position in GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after acquiring an additional 4,085 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in GlucoTrack during the fourth quarter valued at about $52,000. Finally, Ikarian Capital LLC purchased a new stake in GlucoTrack during the fourth quarter valued at about $177,000. 10.92% of the stock is owned by institutional investors.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.